Swiss pharmaceutical giant Novartis announced it will spend $23 billion to build and expand 10 facilities in the United ...

Swiss pharmaceutical company, Novartis, has announced plans to build a new, $1.1 billion biomedical research complex in San ...

Pfizer sold the five-building facility on Science Center Drive in Torrey Pines to BioMed Realty, a San Diego-based firm owned ...

Swiss-pharmaceutical giant, Novartis, announced Thursday that it plans to build a $1.1 billion research hub in San Diego as ...

Landmark Bio brings to Artis state-of-the-art infrastructure and expertise in process development, analytical sciences, and ...

It is part of a planned $23 billion investment over the next five years aimed at expanding its U.S.-based infrastructure.

Pfizer is officially bidding adieu to its sprawling research site in San Diego as it readjusts its local footprint and moves into a new site. | The company is moving its oncology R&D digs in San Diego ...

Novartis will invest $23bn in US-based manufacturing and research and development (R&D) over the next five years, becoming ...

Last year, the San Diego-based Emlyn Group surveyed 250 biotechnology companies in the United States and Canada and received responses from 23 firms. The results of the study were released earlier ...

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

Pharmaceutical companies breathed a sigh of relief on Wednesday, but the tariff reprieve could prove fleeting.